Trial Profile
A Randomized, Double-blind, Placebo-controlled, 2-Part Study of Orally Administered AK0529 to Evaluate the Safety, Tolerability, Pharmacokinetics and Antiviral Effect of Single and Multiple Dosing in Hospitalized Infants With Respiratory Syncytial Virus Infection
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Feb 2024
Price :
$35
*
At a glance
- Drugs Ziresovir (Primary)
- Indications Respiratory syncytial virus infections
- Focus Adverse reactions; Proof of concept
- Acronyms VICTOR
- Sponsors Ark Biosciences
- 08 Jan 2020 According to an Ark Biosciences media release, updates from this study will be presented at the JP Morgan Healthcare Conference on January 15th 2020.
- 05 Nov 2019 Results published in Ark Bioscience Media Release
- 05 Nov 2019 According to Ark Biosciences media release, detailed clinical results will be published and reported at medical conferences in due course